Troy A. Ignelzi - 17 Jan 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Troy Ignelzi
Issuer symbol: N/A
Transactions as of: 17 Jan 2023
Net transactions value: -$195,224
Form type: 4
Filing time: 19 Jan 2023, 15:45:55 UTC
Previous filing: 19 Dec 2022
Next filing: 13 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$7,516	+817	+3.7%	$9.20^*	22,654	17 Jan 2023	Direct
transaction	KRTX	Common Stock	Sale	$164,552	-817	-3.6%	$201.41	21,837	17 Jan 2023	Direct	F1
transaction	KRTX	Common Stock	Options Exercise	$1,840	+200	+0.92%	$9.20^*	22,037	18 Jan 2023	Direct
transaction	KRTX	Common Stock	Sale	$40,028	-200	-0.91%	$200.14	21,837	18 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-817	-0.74%	$0.000000	109,926	17 Jan 2023	Common Stock	817	$9.20	Direct	F2
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-200	-0.18%	$0.000000	109,726	18 Jan 2023	Common Stock	200	$9.20	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
F2	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.